2023
DOI: 10.1016/j.jtcvs.2021.03.016
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
23
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 27 publications
(24 citation statements)
references
References 29 publications
0
23
1
Order By: Relevance
“…Standardizing the definition of AKI into the KDIGO definition (and its predecessors) has advanced our understanding of AKI and improved epidemiologic AKI research. Newer biomarkers may be able to quickly and accurately diagnose kidney injury and specify patient phenotypes, including those whose AKI will persist (longer duration) or progress (worsen severity) [6][7][8][9]. There are growing calls for these biomarkers to be incorporated into routine clinical practice for use in risk stratification and diagnosis of AKI [10,11].…”
Section: Stage Creatininementioning
confidence: 99%
“…Standardizing the definition of AKI into the KDIGO definition (and its predecessors) has advanced our understanding of AKI and improved epidemiologic AKI research. Newer biomarkers may be able to quickly and accurately diagnose kidney injury and specify patient phenotypes, including those whose AKI will persist (longer duration) or progress (worsen severity) [6][7][8][9]. There are growing calls for these biomarkers to be incorporated into routine clinical practice for use in risk stratification and diagnosis of AKI [10,11].…”
Section: Stage Creatininementioning
confidence: 99%
“…In this metric, CCL14 performed better than several frequently investigated biomarkers, including urinary neutrophil gelatinase-associated lipocalin, liver fatty acid binding protein, IL-18, tissue inhibitor of metalloproteinases-2, IGF-binding protein 7, kidney injury molecule-1, and plasma cystatin C. The performance of CCL14, however, was not statistically different from that of serum creatinine at the time of enrollment (AUC50.81; 95% CI, 0.76 to 0.86, P50.63). The association between CCL14 and AKI persistence has since been replicated in two additional studies with comparable predictive performance (21,22).…”
mentioning
confidence: 74%
“…12 These findings were recently validated in a separate cohort of patients with severe AKI following cardiac surgery. 13 Novel biomarkers can provide valuable data in prognosticating which patients will progress from an AKI perspective, allowing for the identification of those destined for a rapid kidney recovery versus those who may benefit from measures to prevent progression to acute and chronic kidney disease.…”
Section: Novel Urine Biomarkers: the Future Of Aki Care Is Herementioning
confidence: 99%
“…Ashley La: Conceptualization; Writing -original draft Jay Koyner: Conceptualization; Writing -review and editing 13…”
Section: Disclosuresmentioning
confidence: 99%